GLP-1 Market
LLY $1170.14 ▲ +0.5% NVO $39.40 ▼ -1.0% PFE $27.93 ▲ +0.7% VKTX $40.85 ▲ +35.7% KLRA $12.79 ▲ +6.7% GPCR $36.91 ▲ +0.3% RHHBY $55.56 ▲ +0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Donanemab

Company
Eli Lilly and Company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
6 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

6 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 23, 2026

Find a Clinical Trial Near Me

See recruiting studies for Donanemab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06566170

    A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

    Eli Lilly and Company 6250 participants Est. completion 2033-02 1 site
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Recruiting NCT NCT06957418

    Alzheimer's Tau Platform: Master Protocol

    Not yet reported Paul S. Aisen 900 participants Est. completion 2028-08-31 3 sites Stand-alone
    Other conditions: Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
    View official trial listing →
  • Recruiting NCT NCT06996730

    A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

    Not yet reported, Not yet reported Banner Health 240 participants Est. completion 2030-06-01 1 site Stand-alone
    Other conditions: Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease, Alzheimers Disease
    View official trial listing →
  • Recruiting NCT NCT07571161

    Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

    Not yet reported Eli Lilly and Company 140 participants Est. completion 2030-04 30 sites Stand-alone
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Recruiting NCT NCT07589595

    A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

    Not yet reported Eli Lilly and Company 350 participants Est. completion 2028-08 72 sites Stand-alone
    Other conditions: Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
    View official trial listing →
  • Recruiting NCT NCT07602582

    A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    Not yet reported Eli Lilly and Company 550 participants Est. completion 2029-09 59 sites Stand-alone
    Other conditions: Alzheimer Disease, Dementia, Plaque, Amyloid
    View official trial listing →
  • Completed NCT NCT01837641

    A Study of LY3002813 in Participants With Alzheimer's Disease

    Not yet reported Eli Lilly and Company 63 participants Est. completion 2016-08-24 6 sites Stand-alone
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT02624778

    A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

    Not yet reported Eli Lilly and Company 61 participants Est. completion 2019-08-28 9 sites Stand-alone
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT03367403

    A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

    Not yet reported Eli Lilly and Company 272 participants Est. completion 2021-09-21 61 sites Stand-alone
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Active, not recruiting NCT NCT04437511

    A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

    Not yet reported Eli Lilly and Company 1736 participants Est. completion 2028-11 274 sites Stand-alone
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT04640077

    A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

    Not yet reported Eli Lilly and Company 95 participants Est. completion 2024-02-27 27 sites Stand-alone
    Other conditions: Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment
    View official trial listing →
  • Active, not recruiting NCT NCT05026866

    A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

    Not yet reported Eli Lilly and Company 2996 participants Est. completion 2027-11 216 sites Stand-alone
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT05108922

    A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

    Not yet reported Eli Lilly and Company 148 participants Est. completion 2023-09-19 31 sites Stand-alone
    Other conditions: Mild Cognitive Impairment (MCI), Alzheimer Disease
    View official trial listing →
  • Active, not recruiting NCT NCT05508789

    A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

    Not yet reported Eli Lilly and Company 1500 participants Est. completion 2028-07 141 sites Stand-alone
    Other conditions: Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
    View official trial listing →
  • Completed NCT NCT05533411

    A Study of Donanemab (LY3002813) in Healthy Chinese Participants

    Not yet reported Eli Lilly and Company 36 participants Est. completion 2023-01-05 2 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05567159

    A Study of Donanemab (LY3002813) in Healthy Participants

    Not yet reported Eli Lilly and Company 42 participants Est. completion 2023-07-14 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT05738486

    A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

    Not yet reported Eli Lilly and Company 1175 participants Est. completion 2027-05 49 sites Stand-alone
    Other conditions: Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
    View official trial listing →
  • Not yet recruiting NCT NCT06911944

    Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

    Not yet reported Michael Rafii, MD, PhD 60 participants Est. completion 2028-12-31 Stand-alone
    Other conditions: Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Disease, Amyloid Beta Protein
    View official trial listing →
  • Enrolling by invitation NCT NCT07167966

    Alzheimer's Tau Platform: Regimen A - AADvac1

    Not yet reported Paul S. Aisen 450 participants Est. completion 2028-08-31 3 sites Stand-alone
    Other conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
    View official trial listing →
  • Not yet recruiting NCT NCT07456462

    Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance

    Not yet reported IRCCS San Raffaele 50 participants Est. completion 2029-05-01 1 site Stand-alone
    Other conditions: Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI)
    View official trial listing →
  • Not yet recruiting NCT NCT07756294

    Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

    Not yet reported Wake Forest University Health Sciences 30 participants Est. completion 2028-04 1 site
    Other conditions: Alzheimer Disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Donanemab, Kisunla, LY3002813

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.